CSF3R
ENSG00000119535
Target class
Membrane receptor
Chromosome
1
Approved drugs
5
Clinical candidates (approved and in development)
10
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 10
- Chemical probe available
- No
- Target name
- CSF3R
- Gene name
- Colony stimulating factor 3 receptor
- Gene symbol
- CSF3R
- Previous gene symbols
- CD114
- Protein name
- Granulocyte colony-stimulating factor receptor (G-CSF receptor) (G-CSF-R) (CD antigen CD114)
- GCSFR
- G-CSF-R
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Fibronectin type III domain containing
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 52
- Highest tissue expression
- 2,125.6
- Tissue specificity (Gini)
- 0.908
- Tissue specificity (tau)
- 0.992
- KEGG gene identifiers
- hsa:1441
- Protein interaction confidence
- 0.791486
- Protein interaction partners
- 70
- R-HSA-449836
- R-HSA-9616222
- R-HSA-9674555
- R-HSA-9705462
- End position
- 36483322
- Start position
- 36465669
- Chromosome
- 1
- Strand
- Reverse
- [Isoform 2]: Secreted .
- SUBCELLULAR LOCATION: Cell membrane
- Single-pass type I membrane protein .
Publication evidence
- PubMed 24753537
- Tissue specificity (tau)
- 0.992347
- Expression inequality (Gini)
- 0.907879
Expression in transcripts per million
- Whole Blood
- 2,125.6
- Spleen
- 383
- Lung
- 177.4
- Fallopian Tube
- 29.16
- Adipose - Visceral (Omentum)
- 23.07
Expression in transcripts per million
- Whole Blood2,125.6
- Spleen383
- Lung177.4
- Fallopian Tube29.16
- Adipose - Visceral (Omentum)23.07
- Brain - Spinal cord (cervical c-1)14.99
- Breast - Mammary Tissue13.7
- Nerve - Tibial12.26
- Adipose - Subcutaneous11.96
- Bladder10.19
- Artery - Coronary9.16
- Cervix - Endocervix8.69
- Liver8.4
- Brain - Substantia nigra7.95
- Prostate7.76
- Small Intestine - Terminal Ileum7.43
- Artery - Aorta7.31
- Thyroid7.2
- Pituitary6.26
- Heart - Atrial Appendage6.19
- Vagina5.99
- Adrenal Gland5.95
- Brain - Hypothalamus5.77
- Uterus5.73
- Minor Salivary Gland4.99
And 29 more, listed on the interactive page.
Biological processes
- GO:0006952
- GO:0005765
- GO:0005886
- GO:0030666
- GO:0005515
- GO:0038023
Related records
Trials (1,847)
- 131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma
- 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
- 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
- 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
- 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
- 4-step ASCOT in POI Women to Promote Follicular Rescue
- A Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for PEG-G-CSF
- A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
- A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
- A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)
- A Clinical Trial of Immunobridging and Lot-to-lot Consistency of COVID-19 Vaccine (Ad5-nCoV) in Different Age Groups.
- A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)
- A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen
- A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination
- A Clinical Trial on Booster Immunization of Two COVID-19 Vaccines Constructed From Different Technical Routes
- A Clinical Trial on Diabetic Foot Using Peripheral Blood Derived Stem Cells for Treating Critical Limb Ischemia
- A Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cell, NVSI-06-09) and Inactivated COVID-19 Vaccine (Vero Cell)
Drugs (10)
- Anumigilimab Granulocyte colony stimulating factor receptor antagonist
- Balugrastim Granulocyte colony stimulating factor receptor agonist
- Efbemalenograstim alfa Granulocyte colony stimulating factor receptor agonist
- Eflapegrastim Granulocyte colony stimulating factor receptor agonist
- Filgrastim Granulocyte colony stimulating factor receptor agonist
- Lenograstim Granulocyte colony stimulating factor receptor agonist
- Lipegfilgrastim Granulocyte colony stimulating factor receptor agonist
- Pegfilgrastim Granulocyte colony stimulating factor receptor agonist
- Pegteograstim Granulocyte colony stimulating factor receptor agonist
- Regramostim Granulocyte colony stimulating factor receptor agonist